clinical trial · NCT06840119
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
CancerHLA-A*02:01-positiveIMC-R117CChemotherapy drugChemotherapy drugKinase inhibitorAntiangiogenic AgentMonoclonal antibody
brief summary
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
started
Jan 10, 2024
primary completion
Nov 30, 2026
completion
Nov 30, 2027
last updated
Jan 28, 2026
official title
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol